Kamada announces a global first...
Biopharmaceutical company Kamada Ltd. has announced the availability of its Hyperimmune IgG Therapy for coronavirus disease for compassionate use treatment in Israel. Kamada believes it is the first company in the world to complete the manufacturing of a plasma-derived IgG therapy for COVID-19.
The company intends to initiate a phase 1/2 clinical study in hospitalized COVID-19 patients in Israel during the third quarter of 2020. Kamada and its partner, Kedrion, are also expanding the clinical development program to the US.
“We are extremely pleased with the rapid and important progress achieved to date in advancing our plasma-derived IgG product for COVID-19,” said Amir London, Kamada’s Chief Executive Officer. “To the best of our knowledge, Kamada is the first company globally to complete manufacturing of a plasma-derived IgG product for the treatment of COVID-19.”